For millions with age-related macular degeneration, the center of vision slowly dissolves into grey. Faces become unrecognizable. Road signs fade to blur. Until now, doctors could only slow the damage—not reverse it.
That's changing. In the first clinical trial of its kind, researchers have successfully transplanted stem cells into the eyes of patients with advanced dry macular degeneration, and some of them can see more clearly than they have in years.
How the treatment works
Dry macular degeneration—the most common form—happens when cells supporting the retina gradually break down. Over time, deposits of fat and protein accumulate in the macula, the part of the retina responsible for sharp, focused vision. Existing treatments can slow this process, but they can't repair what's already damaged.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxThe new approach is more direct. Researchers took stem cells derived from eye tissue, grew them in the lab, and injected 50,000 of them under the retina of patients aged 71 to 86. The goal: these fresh cells would replace the damaged ones and restore the retina's support system.
The team at Michigan Medicine started with a small group—a phase 1/2a trial where safety is the primary concern. And the results cleared that hurdle decisively. No immune rejection. No tumors. No serious side effects linked to the stem cells themselves.
But something unexpected happened.
The vision gains caught researchers off guard
Three patients came into the trial with the worst baseline vision—so poor they could barely read the largest letters on an eye chart (measured as 20/200 to 20/800 vision). One year after treatment, each of them could read an average of 21 additional letters. Their untreated eyes saw no improvement, which strongly suggests the stem cells were responsible.
"We were surprised by the magnitude of vision gain," said Rajesh Rao, the ophthalmologist leading the research. "This level of vision gain has not been seen in this group of patients with advanced dry AMD."
That matters because it's not just a statistical win—it's the difference between recognizing a face and seeing a blur. Between reading a menu and guessing. Between the world staying out of reach and coming back into focus.
What happens next
The team is now testing higher doses—150,000 and 250,000 cells—to see whether vision gains scale with cell count and remain safe. If the results hold, phase 3 trials (the final step before regulatory approval) could move forward faster than expected. The real test will be whether this works in larger, more diverse patient populations.
For the millions living with advanced dry AMD, this is the first time a treatment has actually restored vision rather than just slowing its loss. The path from early trial to widely available treatment is still years long. But for the first time, that path leads somewhere worth going.
